Nutrien Ltd vs Teladoc Health Inc — how do they compare? Nutrien Ltd trades at $67.48 (market cap $33.31B), while Teladoc Health Inc trades at $5.79 (market cap $1.01B). The key difference: Nutrien Ltd is far larger — about 33× Teladoc Health Inc's market cap, and Nutrien Ltd pays a 3.15% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Teladoc Health Inc for 39 Days on average.
| NTR | TDOC | |
|---|---|---|
Market Cap | $33.31B | $1.01B |
Volume | 1,330,729 | 4,668,477 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $9.72 |
52-Week Low | $53.64 | $4.47 |
Typical Hold Time | 59 Days | 39 Days |
Enterprise Value | $45.11B | $1.27B |
Dividend Yield | 3.15% | — |
Signals from Pluang's Aura AI — not financial advice
NTR trades at $67.48, down 3.56% over 24 hours, with technical indicators showing a bearish trend. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Financials show a net income margin of 8.44% for 2025, with revenue of $26.89B, while recent news highlights industry headwinds from potential U.S. potash deals with Belarus.
The outlook is cautious; analyst consensus is a Moderate Buy with a $76.14 price target, but near-term risks include volatile fertilizer prices and competitive pressures. Long-term demand for agricultural inputs supports fundamentals, yet investors face cyclical earnings and margin compression risks amid macroeconomic uncertainty.
Teladoc Health (TDOC) trades at $5.77, up 3.78% today but remains near multi-year lows amid ongoing profitability challenges. The stock shows bearish technical signals with mixed earnings performance, having beaten estimates in two of the last three quarters but posting consistent net losses. Recent management changes include the appointment of a new CFO and legal officer as the company focuses on stabilizing its integrated care business while grappling with BetterHelp segment weakness.
While TDOC trades at discounted valuation multiples (P/S 0.4x, P/B 0.77x) and analysts maintain a $8.83 price target, the path to profitability remains uncertain given seven consecutive quarters of negative earnings. The primary investment thesis hinges on the company's ability to monetize its chronic care platform and achieve sustainable free cash flow generation, though investor sentiment remains cautious amid ongoing losses and competitive pressures in virtual healthcare.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →